Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

NCT02045212 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-arteritic Ischemic Optic Neuropathy
Optic Nerve Injuries

Interventions

DRUG: RPh201
DRUG: Placebo

Sponsor

Regenera Pharma Ltd